Literature DB >> 25840598

Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.

Anne-Sophie Michallet1, Yann Guillermin2, Benedicte Deau3, Laure Lebras2, Stephanie Harel4, Sandy Amorin4, Claire Reynes5, Gilles Salles6, Fabien Subtil7, Pauline Brice4.   

Abstract

Entities:  

Keywords:  Hodgkin lymphoma; SGN 35; combined therapy; refractory

Mesh：

Substances：

Year:  2015        PMID： 25840598      PMCID： PMC4486239          DOI： 10.3324/haematol.2015.124784

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Authors:  Norbert Schmitz; Beate Pfistner; Michael Sextro; Markus Sieber; Angelo M Carella; Matthias Haenel; Friederike Boissevain; Reinhart Zschaber; Peter Müller; Hartmut Kirchner; Andreas Lohri; Susanne Decker; Bettina Koch; Dirk Hasenclever; Anthony H Goldstone; Volker Diehl
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

2.  A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Authors:  C H Moskowitz; S D Nimer; A D Zelenetz; T Trippett; E E Hedrick; D A Filippa; D Louie; M Gonzales; J Walits; N Coady-Lyons; J Qin; R Frank; J R Bertino; A Goy; A Noy; J P O'Brien; D Straus; C S Portlock; J Yahalom
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

3.  Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.

Authors:  C G Cerveny; C-L Law; R S McCormick; J S Lenox; K J Hamblett; L E Westendorf; A K Yamane; J M Petroziello; J A Francisco; A F Wahl
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

4.  In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts.

Authors:  Z G Tian; D L Longo; S Funakoshi; O Asai; D K Ferris; M Widmer; W J Murphy
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

5.  Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD.

Authors:  V Bonfante; A Santoro; S Viviani; L Devizzi; M Balzarotti; F Soncini; M Zanini; P Valagussa; G Bonadonna
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

6.  Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

Authors:  A Josting; C Rudolph; M Reiser; M Mapara; M Sieber; H H Kirchner; B Dörken; D K Hossfeld; V Diehl; A Engert
Journal:  Ann Oncol       Date:  2002-10       Impact factor: 32.976

7.  Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines.

Authors:  Friederike Heuck; Julia Ellermann; Peter Borchmann; Achim Rothe; Hinrich Hansen; Andreas Engert; Elke Pogge von Strandmann
Journal:  J Immunother       Date:  2004 Sep-Oct       Impact factor: 4.456

8.  Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.

Authors:  D L Longo; P L Duffey; R C Young; S M Hubbard; D C Ihde; E Glatstein; J C Phares; E S Jaffe; W J Urba; V T DeVita
Journal:  J Clin Oncol       Date:  1992-02       Impact factor: 44.544

9.  Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.

Authors:  Franck Morschhauser; Pauline Brice; Christophe Fermé; Marine Diviné; Gilles Salles; Reda Bouabdallah; Catherine Sebban; Laurent Voillat; Olivier Casasnovas; Aspasia Stamatoullas; Krimo Bouabdallah; Marc André; Jean-Philippe Jais; Dominique Cazals-Hatem; Christian Gisselbrecht
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

10.  Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Authors:  Jonathan W Friedberg; Philip Cohen; Ling Chen; K Sue Robinson; Andres Forero-Torres; Ann S La Casce; Luis E Fayad; Alberto Bessudo; Elber S Camacho; Michael E Williams; Richard H van der Jagt; Jennifer W Oliver; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544
View more
  8 in total

1.  Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.

Authors:  Anton Hagenbeek; Hans Mooij; Josée Zijlstra; Pieternella Lugtenburg; Gustaaf van Imhoff; Marcel Nijland; Sanne Tonino; Martin Hutchings; Marjolein Spiering; Roberto Liu; Harm van Tinteren; Marie José Kersten
Journal:  Haematologica       Date:  2018-10-31       Impact factor: 9.941

2.  Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.

Authors:  Peter D Cole; Kathleen M McCarten; Qinglin Pei; Menachem Spira; Monika L Metzger; Richard A Drachtman; Terzah M Horton; Rizvan Bush; Susan M Blaney; Brenda J Weigel; Kara M Kelly
Journal:  Lancet Oncol       Date:  2018-08-16       Impact factor: 41.316

3.  Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.

Authors:  Aurore Perrot; Hélène Monjanel; Réda Bouabdallah; Philippe Quittet; Clémentine Sarkozy; Marc Bernard; Aspasia Stamatoullas; Cécile Borel; Krimo Bouabdallah; Emmanuelle Nicolas-Virelizier; Marion Fournier; Franck Morschhauser; Pauline Brice
Journal:  Haematologica       Date:  2016-01-14       Impact factor: 9.941

Review 4.  Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.

Authors:  Anna Alperovich; Anas Younes
Journal:  Cancer J       Date:  2016 Jan-Feb       Impact factor: 3.360

5.  Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.

Authors:  Maria K Angelopoulou; Theodoros P Vassilakopoulos; Ioannis Batsis; Ioanna Sakellari; Konstantinos Gkirkas; Vasiliki Pappa; Panagiota Giannoulia; Ioannis Apostolidis; Christos Apostolopoulos; Paraskevi Roussou; Panayiotis Panayiotidis; Maria Dimou; Marie-Christine Kyrtsonis; Maria Palassopoulou; Georgios Vassilopoulos; Maria Moschogiannis; Christina Kalpadakis; Dimitrios Margaritis; Alexander Spyridonidis; Eurydiki Michalis; Konstantinos Anargyrou; Panagiotis Repousis; Eleutheria Hatzimichael; Zoi Bousiou; Elias Poulakidas; Dimitrios Grentzelias; Nikolaos Harhalakis; Gerassimos A Pangalis; Achilles Anagnostopoulos; Panagiotis Tsirigotis
Journal:  Hematol Oncol       Date:  2017-02-20       Impact factor: 5.271

Review 6.  Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review.

Authors:  Eva M Donato; Miguel Fernández-Zarzoso; Jose Antonio Hueso; Javier de la Rubia
Journal:  Onco Targets Ther       Date:  2018-08-06       Impact factor: 4.147

7.  [Interstitial pneumonia in patients with diffuse large B-cell lymphoma receiving RCHOP and RCDOP regimens].

Authors:  Y N Meng; S Wang; Q Shi; P P Xu; S Cheng; L Wang; W L Zhao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-12-14

8.  Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study.

Authors:  Amira Marouf; Anne Segolene Cottereau; Salim Kanoun; Paul Deschamps; Michel Meignan; Patricia Franchi; David Sibon; Clara Antoine; Thomas Gastinne; Cecile Borel; Mohammad Hammoud; Guillaume Sicard; Romane Gille; Doriane Cavalieri; Aspasia Stamatoullas; Lauriane Filliatre-Clement; Julien Lazarovici; Adrien Chauchet; Luc-Matthieu Fornecker; Sandy Amorin; Mathieu Rocquet; Nicole Raus; Barbara Burroni; Marie Therese Rubio; Didier Bouscary; Philippe Quittet; Rene Olivier Casasnovas; Pauline Brice; Herve Ghesquieres; Jérôme Tamburini; Benedicte Deau
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.